| Autor: |
Johnson KP; University of Maryland, Baltimore, MD, USA. kjohnson@som.umaryland.edu, Due DL |
| Jazyk: |
angličtina |
| Zdroj: |
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2009 Jun; Vol. 9 (3), pp. 205-14. |
| DOI: |
10.1586/erp.09.20 |
| Abstrakt: |
Relapsing-remitting multiple sclerosis is a chronic, progressive disorder marked by repeated exacerbations that lead to increases in neurological disability. Glatiramer acetate and the IFN-betas are recommended as first-line agents for relapsing-remitting multiple sclerosis owing to their potential to reduce frequency and severity of relapses, decrease development of new brain lesions and delay permanent disability. After three decades of study, the preponderance of the evidence suggests that the efficacy of glatiramer acetate is similar to the IFN-betas and new data collected in more naturalistic settings suggest that it may provide improved quality of life, increased productivity and cost-effectiveness. This article will review this evidence including data from very recent head-to-head clinical trials and pharmacoeconomic analyses of cost-effectiveness. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
